Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2012

01-10-2012 | Research Article

Drug use before and during pregnancy in Serbia

Authors: Marina Odalovic, Sandra Vezmar Kovacevic, Katarina Ilic, Ana Sabo, Ljiljana Tasic

Published in: International Journal of Clinical Pharmacy | Issue 5/2012

Login to get access

Abstract

Background Observation of drug use patterns during pregnancy is necessary for the recognition of potential bad practices and improvement of safe drug use in pregnancy. Objective To investigate prescription and over the counter drug use among Serbian women in the 6 months before pregnancy and in the first 6 months of pregnancy, and to evaluate the drugs used according to the risk to a fetus. Setting Six maternity care units and five community pharmacies Method A multi-center study was performed in Serbia during the period from March 2009–March 2010. A self-reporting questionnaire was used as a data source. Food and Drug Administration (FDA) risk classification system was used to determine the risk of used drugs for the fetus. Differences between subgroups were assessed using McNemar’s test on paired proportions. Main outcome measure Proportion of women exposed to drugs or class of drugs. Results The overall drug exposure was higher in pregnancy (34.7 %) than before pregnancy (29.9 %), p > 0.05, in the cohort of 311 pregnant women. A significantly greater prescription drug use, 19.0 versus 27.3 % of women, p < 0.05, and less selfmedication with over the counter drugs in pregnancy, 15.1 versus 8.7 %, p < 0.05, were observed. Commonly used drugs were musculoskeletal drugs, analgesics/antipyretics and respiratory system drugs before pregnancy (13.8, 12.5, and 6.4 % of women, respectively), and progestogens, analgesics/antipyretics, and antibiotics for the systemic use in pregnancy (9.0, 7.7, and 7.4 %, respectively). A greater exposure to drugs belonging to the FDA risk category A (3.9 vs. 60.8 %, p < 0.05), B (18.0 vs. 19.6 %, p > 0.05), C (10.0 vs. 10.3 %, p > 0.05) and D (2.9 vs. 10.9 %, p < 0.05), as well as less exposure to drugs belonging to category X (0.3 vs. 0 %, p > 0.05) were observed in pregnancy. Folic acid was used by 60.8 % of women in pregnancy, and by only 3.9 % before pregnancy. Conclusion Besides higher overall drug use in pregnancy than before pregnancy, particularly the use of progestogens, and, subsequently, D category drugs, less selfmedication with over the counter drugs was observed in pregnancy. Insufficient use of folic acid before pregnancy requires public health service activities.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Leck IM, Millar EL. Incidence of malformations since the introduction of thalidomide. BMJ. 1962;2(5296):16–20.PubMedCrossRef Leck IM, Millar EL. Incidence of malformations since the introduction of thalidomide. BMJ. 1962;2(5296):16–20.PubMedCrossRef
3.
go back to reference Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157C(3):175–82. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157C(3):175–82.
4.
go back to reference Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann. 2010;41(4):241–50.PubMedCrossRef Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann. 2010;41(4):241–50.PubMedCrossRef
5.
go back to reference Finnell RH. Teratology: general considerations and principles. J Allergy Clin Immunol. 1999;103(2):S337–42.PubMedCrossRef Finnell RH. Teratology: general considerations and principles. J Allergy Clin Immunol. 1999;103(2):S337–42.PubMedCrossRef
8.
go back to reference Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 8th ed. Philadelphia: Lippincott Wiliams & Wilkins; 2008. ISBN: 978-0-7817-7876-3. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 8th ed. Philadelphia: Lippincott Wiliams & Wilkins; 2008. ISBN: 978-0-7817-7876-3.
9.
go back to reference Sipetic T. National formulary. Belgrade: Medicines and Medical Devices Agency of Serbia; 2010. Sipetic T. National formulary. Belgrade: Medicines and Medical Devices Agency of Serbia; 2010.
10.
go back to reference De Vigan C, De Walle HEK, Cordier S, Goujard J, Knill-Jones R, Ayme S, et al. Therapeutic drug use during pregnancy: a comparison in four European countries. J Clin Epidemiol. 1999;52(10):977–82.PubMedCrossRef De Vigan C, De Walle HEK, Cordier S, Goujard J, Knill-Jones R, Ayme S, et al. Therapeutic drug use during pregnancy: a comparison in four European countries. J Clin Epidemiol. 1999;52(10):977–82.PubMedCrossRef
11.
go back to reference Kebede B, Gedif T, Getachew A. Assessment of drug use among pregnant women in Addis Ababa. Ethiopia. Pharmacoepidemiol Drug Saf. 2009;18(6):462–8.CrossRef Kebede B, Gedif T, Getachew A. Assessment of drug use among pregnant women in Addis Ababa. Ethiopia. Pharmacoepidemiol Drug Saf. 2009;18(6):462–8.CrossRef
12.
go back to reference Rohra DK, Das N, Azam SI, Solangi NA, Memon Z, Shaikh AM, et al. Drug-prescribing patterns during pregnancy in the tertiary care hospitals of Pakistan: a cross sectional study. BMC Pregnancy Childbirth. 2008;8:24–8.PubMedCrossRef Rohra DK, Das N, Azam SI, Solangi NA, Memon Z, Shaikh AM, et al. Drug-prescribing patterns during pregnancy in the tertiary care hospitals of Pakistan: a cross sectional study. BMC Pregnancy Childbirth. 2008;8:24–8.PubMedCrossRef
13.
go back to reference Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HEK, De Jong-Van Den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG. 2006;113(5):559–68.PubMedCrossRef Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HEK, De Jong-Van Den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG. 2006;113(5):559–68.PubMedCrossRef
14.
go back to reference Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398–407.PubMedCrossRef Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398–407.PubMedCrossRef
15.
go back to reference Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol. 2004;60(9):659–66.PubMedCrossRef Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol. 2004;60(9):659–66.PubMedCrossRef
16.
go back to reference Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H. Drug use during pregnancy in Sweden—assessed by the prescribed drug register and the medical birth register. Clin Epidemiol. 2011;3(1):43–50.PubMed Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H. Drug use during pregnancy in Sweden—assessed by the prescribed drug register and the medical birth register. Clin Epidemiol. 2011;3(1):43–50.PubMed
17.
go back to reference Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106 000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol. 2008;65(5):653–60.PubMedCrossRef Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106 000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol. 2008;65(5):653–60.PubMedCrossRef
18.
go back to reference Nordeng H, Eskild A, Nesheim BI, Jacobsen G. Drug use in pregnancy among parous Scandinavian women. Norsk Epidemiologi. 2001;11:97–103. Nordeng H, Eskild A, Nesheim BI, Jacobsen G. Drug use in pregnancy among parous Scandinavian women. Norsk Epidemiologi. 2001;11:97–103.
19.
go back to reference Headley J, Northstone K, Simmons H, Golding J. Medication use during pregnancy: data from the Avon longitudinal study of parents and children. Eur J Clin Pharmacol. 2004;60(5):355–61.PubMedCrossRef Headley J, Northstone K, Simmons H, Golding J. Medication use during pregnancy: data from the Avon longitudinal study of parents and children. Eur J Clin Pharmacol. 2004;60(5):355–61.PubMedCrossRef
20.
go back to reference Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, Sørensen HT, et al. Drug use in first pregnancy and lactation: a population-based survey among Danish women. Eur J Clin Pharmacol. 1999;55(2):139–44.PubMedCrossRef Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, Sørensen HT, et al. Drug use in first pregnancy and lactation: a population-based survey among Danish women. Eur J Clin Pharmacol. 1999;55(2):139–44.PubMedCrossRef
21.
go back to reference Malm H, Martikainen J, Klaukka T, Neuvonen PJ. Prescription drugs during pregnancy and lactation—a Finnish register-based study. Eur J Clin Pharmacol. 2003;59(2):127–33.PubMed Malm H, Martikainen J, Klaukka T, Neuvonen PJ. Prescription drugs during pregnancy and lactation—a Finnish register-based study. Eur J Clin Pharmacol. 2003;59(2):127–33.PubMed
23.
go back to reference Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Sys Rev. 2008;2:CD003511. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Sys Rev. 2008;2:CD003511.
24.
go back to reference Donati S, Baglio G, Spinelli A, Grandolfo ME. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol. 2000;56(4):323–8.PubMedCrossRef Donati S, Baglio G, Spinelli A, Grandolfo ME. Drug use in pregnancy among Italian women. Eur J Clin Pharmacol. 2000;56(4):323–8.PubMedCrossRef
25.
go back to reference De-Regil LM, Fernández-Gaxiola AC, Dowswell T, Peńa-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2010;10:007950. De-Regil LM, Fernández-Gaxiola AC, Dowswell T, Peńa-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2010;10:007950.
27.
go back to reference Law R, Bozzo P, Koren G, Einarson A. FDA pregnancy risk categories and the CPS: do they help or are they a hindrance? Can Fam Physician. 2010;56(3):239–41.PubMed Law R, Bozzo P, Koren G, Einarson A. FDA pregnancy risk categories and the CPS: do they help or are they a hindrance? Can Fam Physician. 2010;56(3):239–41.PubMed
28.
go back to reference Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB. Safety of medications prescribed before and during early pregnancy in a cohort of 81 975 mothers from the UK general practice research database. Pharmacoepidemiol Drug Saf. 2006;15(8):555–64.PubMedCrossRef Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB. Safety of medications prescribed before and during early pregnancy in a cohort of 81 975 mothers from the UK general practice research database. Pharmacoepidemiol Drug Saf. 2006;15(8):555–64.PubMedCrossRef
29.
go back to reference Yang T, Walker MC, Krewski D, Yang Q, Nimrod C, Garner P, et al. Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf. 2008;17(3):270–7.PubMedCrossRef Yang T, Walker MC, Krewski D, Yang Q, Nimrod C, Garner P, et al. Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf. 2008;17(3):270–7.PubMedCrossRef
30.
go back to reference Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf. 2006;15(8):546–54.PubMedCrossRef Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf. 2006;15(8):546–54.PubMedCrossRef
31.
go back to reference Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2010;20(9):895–902. Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2010;20(9):895–902.
32.
go back to reference Olesen C, Søndergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, Olsen J, EuroMAP Group. Do pregnant women report use of dispensed medications? Epidemiology. 2001;12(5):497–501.PubMedCrossRef Olesen C, Søndergaard C, Thrane N, Nielsen GL, de Jong-van den Berg L, Olsen J, EuroMAP Group. Do pregnant women report use of dispensed medications? Epidemiology. 2001;12(5):497–501.PubMedCrossRef
Metadata
Title
Drug use before and during pregnancy in Serbia
Authors
Marina Odalovic
Sandra Vezmar Kovacevic
Katarina Ilic
Ana Sabo
Ljiljana Tasic
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2012
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9665-8

Other articles of this Issue 5/2012

International Journal of Clinical Pharmacy 5/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.